Company news
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) news
Black Diamond Therapeutics, Inc. news releases on 6ix. Latest, Sep 2, 2026: Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global…
Press releases & updates
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
BioCardia : Aug 24 - BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-on De Novo Pre-submission For Approval
August 24, 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
April 20, 2026
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 16, 2026
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
January 28, 2026
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
December 3, 2025
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
December 2, 2025
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 6, 2025
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 6, 2025
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2025
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
March 19, 2025
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 6, 2025
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 4, 2024
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
October 6, 2024
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
September 22, 2024
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
September 21, 2024
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 5, 2024
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2024
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2024
Black Diamond Therapeutics Announces Changes to Board of Directors
April 10, 2024
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
April 6, 2024
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
March 4, 2024
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
January 3, 2024
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
December 12, 2023
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 5, 2023
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
October 13, 2023
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 3, 2023
Black Diamond Therapeutics Announces CEO Transition
September 17, 2023
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
September 10, 2023
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
June 28, 2023
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2023
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
June 26, 2023
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
June 12, 2023
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
June 1, 2023
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
April 17, 2023
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
April 16, 2023
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 8, 2023
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 26, 2023